Objective: Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study. Methods: This study (NCT01193153) included both in-and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity. Results: 334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M (n = 164) or placebo (n = 170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase (P ≤ 0.008). Conclusion: The analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo.
Introduction
Schizoaffective disorder (SCA) is a serious mental illness characterized by mixed symptoms of schizophrenia and affective disorders (American Psychiatric Association, 2013; Malaspina et al., 2013) . Functional impairment, though not a diagnostic criterion, is commonly observed and is a major adverse outcome for patients and public health Marneros et al., 1990) . Consequently, improving and preserving functioning is an important long-term treatment goal for better prognosis, recovery, and community adjustment Marneros et al., 1990) . According to consensus statements formulated by the Schizoaffective Disorder Working Group, longitudinal assessment of functioning in response to treatment should be performed using appropriate tools, such as the Personal and Social Performance (PSP) scale . The PSP scale is a validated clinician-reported instrument that has been widely used in clinical trials to assess personal and social functioning of patients with psychiatric disorders based on four distinct domains: (A) socially useful activities, (B) personal/social relationships, (C) self-care, and (D) disturbing/aggressive behavior (Morosini et al., 2000; Nasrallah et al., 2008) . Domains A, B, and C represent the functional assessments in Criterion B of schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). The PSP scale provides quantitative measures of patient functioning that are separate from disease-specific symptoms (Morosini et al., 2000) .
Pharmacologic regimens, including antipsychotics, mood stabilizers, and antidepressants, are a mainstay of treatment for patients with SCA (McElroy et al., 1999; Flynn et al., 2002; Lerner et al., 2004) . However, adherence to a daily oral treatment regimen is often difficult (Karve et al., 2014; Alphs et al., 2016) , and medication gaps may contribute to suboptimal treatment response and poorer long-term outcomes (Lindenmayer et al., 2009; Boden et al., 2011) . Advances and innovations in treatment options over the past decade have improved the outlook for patients with SCA (Canuso et al., 2010) or schizophrenia, particularly the development of long-acting injectable (LAI) antipsychotic therapies (Fu et al., 2015; Lindenmayer and Kaur, 2016; Alphs et al., 2016; Parellada and Bioque, 2016; Potkin and Preda, 2016; Citrome, 2016; McDonnell et al., 2014) . LAIs provide therapeutic plasma concentrations over several weeks, thereby eliminating the need for daily oral antipsychotic therapy. LAIs allow clinicians to directly monitor adherence (Pandina et al., 2010; Pandina et al., 2011) , and thereby potentially reduce risk of relapse and improve and/or maintain functioning. A 15-month, randomized, double-blind (DB), placebo-controlled relapse-prevention trial of subjects with SCA evaluated the long-term efficacy and safety of once-monthly paliperidone palmitate (PP1M) given either as monotherapy or in combination with antidepressants or mood stabilizers (Fu et al., 2015) . Results demonstrated that PP1M significantly delayed time to relapse and reduced the risk of psychotic, depressive, and manic relapses compared with placebo, resulting in regulatory approval for PP1M in the treatment of SCA (Janssen Pharmaceuticals, Inc., 2014). Furthermore, functioning, as measured by the PSP scale (Morosini et al., 2000) , was better maintained in subjects who received PP1M compared with placebo.
Because personal, social, and occupational functioning are widely recognized as important long-term outcomes in patients with serious mental illness (Burns and Patrick, 2007) , additional PSP analyses from this trial were conducted to examine the dimensions of functioning that were impacted by PP1M treatment (Fu et al., 2015) . The specific objectives of these analyses were twofold: first, to evaluate the effects of treatment with PP1M on each PSP functioning domain during openlabel (OL) treatment of acutely ill patients and, second, to evaluate the ability of PP1M to maintain functioning of stable patients during the DB phase as compared with placebo (i.e., withdrawal of PP1M treatment). The analyses were designed to determine whether the overall functioning observed with the total score is reflected in one, some, or all four PSP domains.
Methods

Study design
This analysis was based on PSP data from a long-term, randomized, DB, placebo-controlled, relapse-prevention international study (NCT01193153) in SCA patients. Study design details have been described (Fu et al., 2015) . Briefly, the study comprised a 25-week OL acute treatment phase and a 15-month DB relapse-prevention phase. The OL phase included a 13-week flexible-dose lead-in period and a 12-week fixed-dose stabilization period. During the lead-in period, all subjects received monthly intramuscular injections of PP1M 234 mg on day 1 and 156 mg on day 8, then flexible doses (78-234 mg) on day 36 and onward as monotherapy or in combination with mood stabilizers or antidepressants (i.e., adjunctive therapy). Subjects who completed the lead-in period and met stabilization criteria (i.e., Positive and Negative Syndrome Scale [PANSS] total score ≤ 70; Young Mania Rating Scale [YMRS] score ≤ 12; and Hamilton Rating Scale for Depression, 21-item version , score ≤ 12) entered the 12-week stabilization period and received PP1M once every 4 weeks at the final dose received during the lead-in period. Subjects who completed the stabilization period and maintained the stabilization criteria throughout the 12-week treatment were eligible to enter the DB phase, and were randomized 1:1 to fixed-dose PP1M or matching placebo injections. Subjects continued to receive PP1M or placebo once every 4 weeks until relapse of SCA symptoms (as defined in Fu et al., 2015) , discontinuation or withdrawal, or until completion of the 15-month DB phase.
The current analysis included the randomized subjects of this multiphase study, whose functioning was evaluated during the 25-week OL acute treatment phase and 15-month DB maintenance treatment phase.
Study population
Men and women aged ≥ 18 years with a lifetime and current diagnosis of SCA, confirmed with the Structured Clinical Interview for DSM-IV, were eligible. Subjects must have had an acute exacerbation of psychotic symptoms of ≥ 4 days and ≤ 4 weeks before screening; prominent mood symptoms (scores ≥ 16 on YMRS and/or HAM-D-21), and a score of ≥4 on ≥ 3 of the PANSS items: P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior), P4 (excitement), P6 (suspiciousness/persecution), P7 (hostility), G4 (tension), G8 (uncooperativeness), and G14 (poor impulse control); and willingness to accept an LAI medication.
Assessments
The effect of PP1M on subject functioning measured by the PSP was a predefined key secondary endpoint (Fu et al., 2015) . Functioning, as clinician measured monthly by the PSP scale, included (A) socially useful activities (i.e., work or school, household chores, and volunteer work or group activities), (B) personal/social relationships (i.e., partner, family and/or friends, and support system outside of treatment), (C) selfcare (i.e., bathing/showering, washing hair, brushing teeth, changing clothes, taking medication, or eating), and (D) disturbing/aggressive behavior (i.e., speaking too loudly, cursing, verbal threats, breaking or throwing objects, fighting, and threatening to harm self or others) (Nasrallah et al., 2008) . Mental health professionals who were trained as raters administered the PSP scale. Raters were instructed to consider all information available from subjects, family members, and other healthcare professionals. Each PSP domain was assessed on a 6-point severity scale of dysfunction: 1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe (Morosini et al., 2000) . We defined no impairment to mild impairment as a PSP domain score of absent or mild dysfunction; moderate to severe impairment was defined as manifest, marked, severe, or very severe dysfunction. After each domain was scored, raters determined a PSP total score by selecting a 10-point range within a 100-point scale based on the domain scores following PSP scoring guidelines (Morosini et al., 2000; Nasrallah et al., 2008) . All 10-point ranges in the scale are described in terms of two components: (1) the scores assigned to domains A to C and (2) score assigned to domain D. Domains A to C contributed equally, but domain D was given additional weight in determining the appropriate 10-point range. Within the 10-point range, raters selected a score based on clinical judgment (Nasrallah et al., 2008) . This final composite PSP score represented the PSP total score. Scores of 71 to 100 signified overall good functioning, scores of 31 to 70 represented functional difficulty requiring external support (variable functioning), and scores ≤30 indicated the need for intensive supervision (poor functioning) (Morosini et al., 2000) .
Statistical analysis
This analysis used the DB intent-to-treat analysis set, which included all randomized subjects who entered the OL phase and received ≥ 1 study medication injection during the DB phase. Change from baseline was evaluated using a paired t-test. Shifts from OL baseline were assessed using a McNemar's test. In the DB phase, PSP total score was analyzed as a continuous endpoint using a mixed model repeated measures (MMRM) approach (Verbeke and Molenberghs, 2000; Diggle et al., 2002) . Differences between treatment groups were also evaluated based on the Cochran-Mantel-Haenszel mean score test using modified ridit scores, stratified by concomitant medication stratum and country. To further evaluate the clinical relevance of the PSP results, time to ≥ 10-points worsening in PSP total score (Nicholl et al., 2010) was evaluated using Kaplan-Meier estimates, and treatment differences were compared using a log-rank test and hazard ratios. The time from no impairment to mild impairment domain scores to moderate to severe impairment domain scores was also evaluated using Kaplan-Meier estimates for each domain. Differences in PSP total and domain scores were also evaluated in subjects who received PP1M as adjunctive therapy (mood stabilizers or antidepressants) and in those who received PP1M as monotherapy.
Three statistical approaches analyzing PSP as three variable types were carried out to assess the robustness and consistency of findings in functioning at study endpoint: PSP score as a continuous variable, PSP score as a categorical variable, and time to clinically significant decrements in PSP score. Each statistical approach provided results and allowed interpretations that contributed to the totality of the PP1M treatment effects on improving and maintaining patient functioning in PSP domains and total scores. No adjustments were made for multiplicity.
Results
Subjects and disposition
A total of 667 subjects were enrolled in the 25-week OL phase. Of the enrolled subjects, 334 were stabilized during the OL phase and were subsequently randomly assigned to PP1M (n = 164) or placebo (n = 170) in the DB phase (Fu et al., 2015) . These 334 subjects were the study population for the current analysis; the remaining 333 subjects discontinued the study prior to randomization. The demographics and baseline characteristics of the overall OL and DB populations are described elsewhere (Fu et al., 2015) .
3.2. Impact of PP1M acute treatment on PSP scores (OL phase)
PSP total scores
In the overall OL population, clinically meaningful improvements in PSP total scores were observed with PP1M by week 5 and maintained until OL endpoint, with a mean (SD) increase of 20.8 (13.3) points at week 25 from OL baseline (Fu et al., 2015) . PSP total scores shifted from predominantly variable functioning at baseline to predominantly good functioning at OL endpoint (Fig. 1). 
PSP domain scores
Baseline PSP domain scores in this data set were characterized by significant levels of dysfunction in areas of socially useful activities and personal/social relationships ( Fig. 2A and B) and some level of impairment in self-care and disturbing/aggressive behaviors ( Fig. 2C and  D) . At OL endpoint, significant shifts toward mild/absent impairment were observed in all four domains. In socially useful activities and personal/social relationships, PSP scores shifted from categories of manifest or severe impairment to mild/absent impairment. In self-care and disturbing/aggressive behaviors, PSP domain scores shifted from manifest or marked impairment to mild/absent impairment.
Impact of maintenance treatment on PSP scores (DB phase)
PSP total scores
Improvements in PSP total scores observed during the OL phase were maintained during the DB phase with PP1M, but decreased with placebo (Fig. 1) . A significant difference (P = 0.014) in favor of PP1M was demonstrated when comparing the mean change from DB baseline to month 15 (week 64) using the MMRM approach. The proportion of subjects with good functioning decreased from 50.6% at DB baseline to 41.1% at 15-month DB endpoint in the placebo group, whereas subjects maintained on PP1M sustained good functioning with 57.9% at DB baseline and 59.0% at DB endpoint ( Fig. 1 ; between-group comparison, P = 0.004). There was no significant difference in PSP total score in subjects receiving PP1M as adjunctive therapy and in those receiving PP1M as monotherapy at any time during the OL or DB phases (all comparisons, P N 0.05). The proportion of subjects with a ≥ 10-points worsening in PSP total scores was similar in the placebo and PP1M groups for the first 3 months of the DB phase (Fig. 3) . Thereafter, a greater proportion of subjects who received placebo had ≥ 10-points worsening in PSP total scores than those who were maintained on PP1M (P b 0.007).
PSP domain scores
At DB baseline, the placebo and PP1M groups had similar PSP scores in all four domains. Compared with the placebo group, a numerically higher percentage of the PP1M group had absent or mild impairment in the domain of socially useful activities, including work and school, but this difference was not statistically significant. At DB endpoint, the level of functioning in all four PSP domains was maintained with continued PP1M treatment, but decreased following the switch to placebo (P ≤ 0.008 for all comparisons) ( Fig. 2A-D) . Kaplan-Meier plots of time from no impairment to mild impairment at DB baseline to moderate to severe impairment for each PSP domain are shown in Fig. 4 . In all domains, significantly more subjects in the placebo group than in the PP1M group moved from no impairment to mild impairment to moderate to severe impairment (P ≤ 0.042 for all comparisons). There was no significant difference in PSP domain scores in subjects receiving PP1M as adjunctive therapy and in those receiving PP1M as monotherapy at any time during the OL or DB phases using chi-square tests (all comparisons, P N 0.05). 
Discussion
PSP analyses from this randomized, DB, placebo-controlled, relapse-prevention trial (Fu et al., 2015) suggest that, in addition to improving the level of functioning of SCA in the OL acute treatment phase for patients completing the OL phase, PP1M sustains the improvement in functioning in the DB maintenance phase as measured by PSP total scores. These findings confirm and extend the primary analysis of this work (Fu et al., 2015) and are consistent with those of other LAI studies that have reported similar effects on functioning in subjects with schizophrenia or SCA (Williams et al., 2014; Apiquian et al., 2010) . In addition, examination of the domain scores reported here allows for a more detailed understanding of functioning over time.
The treatment of acutely ill subjects with PP1M during the OL phase was associated with improvement in all four domains of functioning. There was a substantial shift toward mild to absent impairment in the domains of socially useful activities, including work and study, and personal/social relationships during the OL phase, and these improvements were maintained in the DB phase in the PP1M group. These shifts are noteworthy because improvements in these domains may potentially be indicators of improved productivity, integration into society, and recovery, and they are especially important to patients and their families. These data suggest that tracking socially useful activities and personal/ social relationships may be most impactful for identifying improvements in functioning for patients with SCA.
Most subjects enrolled in this study exhibited poor functioning in the areas of socially useful activities and social relationships at the Subjects at risk, n Estimated proportion of subjects who maintained no impairment or mild impairment outset. Few subjects were characterized as having poor functioning in the areas of self-care or disturbing/aggressive behavior. This may relate to the fact that most subjects were outpatients at the time of enrollment, and subjects with disturbing/aggressive behavior were unlikely to be enrolled in the study. During the DB phase, significantly more subjects in the placebo group had ≥ 10-points worsening in PSP total scores compared with those randomly assigned to continue PP1M maintenance treatment. Additionally, subjects who continued PP1M treatment maintained functioning in all PSP domains, whereas subjects withdrawn from PP1M to placebo showed deterioration in all domains of functioning, with significantly more subjects in the placebo group shifting from no impairment to mild impairment to moderate to severe impairment. Worsening of functioning was most pronounced in socially useful activities and personal/social relationships, the domains in which poorer functioning was seen at study entry.
In the DB phase of the study, no dose adjustment was allowed. The interval between the last dose of PP1M in the OL phase and the first placebo treatment was 1 month. The median apparent half-life of paliperidone following single-dose administration of PP1M is 25 to 49 days. Therefore, subjects randomly assigned to placebo would have had therapeutic plasma levels of paliperidone for at least several weeks after discontinuing PP1M. The expectation that longer half-lives are associated with longer periods of clinical stability following discontinuation of an LAI antipsychotic medication is apparent in the time-toevent graphs for each of the PSP domains. At earlier time points there was no separation between placebo and PP1M arms. In some instances, the survival figures cross each other; this resulted in decreased power in statistical analysis and may have biased results against the PP1M arm. A proportion of subjects in the PP1M group had worsening in the PSP total scores and domain scores, although this worsening was significantly less severe than in the placebo group. Several study design factors may have contributed to the worsening, including that dose adjustment was not allowed and that there was potential expectation bias due to the 1:1 randomization ratio. The safety and tolerability of PP1M observed in this trial have been extensively described elsewhere (Fu et al., 2015) . The present study has limitations that must be considered when interpreting the results. First, subject eligibility criteria were chosen to minimize confounding factors, such as substance dependence. Second, self-selection biases occurred because all subjects had to be willing to be studied in a clinical trial, accept intramuscular injections, and agree to randomization to continued medication or placebo. Third, the analysis is limited to those subjects who completed the OL phase of the study (i.e., responders with acute treatment). Patients may not have improved enough during the OL phase to meet the stabilization criteria required to enter the DB phase or may have discontinued the study early (Fu et al., 2015) . These selection biases may limit the broad generalizability of results to all patients with SCA followed in clinical practice. Further, the PSP domains of self-care and disturbing/aggressive behaviors were less impaired as compared with other domains throughout the study. Subjects who are highly impaired in the domains of self-care or disturbing/ aggressive behaviors would likely require treatment in a more restrictive setting and are less likely to participate in a relatively intensive, long-term research study. Finally, only one clinician-rated scale (i.e., the PSP) was used to measure functioning. Future studies should include additional assessment tools, such as performance-based measures, self-report measures, and quality of life scale, to provide a more comprehensive assessment about the real-world functioning of these patients.
When identifying relapse in a person who has been clinically stabilized, early intervention is ethically necessary to prevent the severe deterioration that might be expected with prolonged withdrawal of treatment. Relapse criteria were explicitly designed to detect early signs of deterioration, such that subjects identified as experiencing an impending relapse were immediately removed from the study and clinically determined optimal treatment interventions were instituted. During the DB phase of this study, 17 of 82 relapsed subjects required hospitalization: 12 (14.6%) in the placebo group and 5 (6.1%) in the PP1M group. Given ethical requirements, the degree of deterioration in functioning that might have occurred if placebo had been maintained without antipsychotic intervention is not known. It is reasonable to assume that if no early antipsychotic interventions were made, subjects might have returned to their baseline dysfunction. Thus, treatment group differences observed in these study subjects are likely to be less than those seen in a real-world situation in which patients are not followed so carefully.
In conclusion, these results suggest that PP1M improves patient functioning, as measured by the PSP scale, in symptomatic subjects with SCA and maintains good levels of functioning in those who are successfully stabilized on therapy for 6 months. The examination of domains of functioning underscores the impact of sustained treatment on socially useful activities and interpersonal relationships. Further, once subjects are stabilized, PP1M better maintains functioning, compared with randomized withdrawal to placebo (a condition that mimics stopping treatment for any reason in a real-world environment).
This analysis of treatment response within specific domains of functioning may be informative for clinicians as they work with their clients to control symptoms and potentially improve and preserve functioning and mental health recovery. Taken together, this work supports the value of continued treatment with an LAI antipsychotic, such as PP1M, for patients with SCA.
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